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Background: The inclusion of patient preferences (PP) in the medical product life cycle is a topic of growing
interest to stakeholders such as academics, Health Technology Assessment (HTA) bodies, reimbursement agencies,
industry, patients, physicians and regulators. This review aimed to understand the potential roles, reasons for using
PP and the expectations, concerns and requirements associated with PP in industry processes, regulatory benefit-
risk assessment (BRA) and marketing authorization (MA), and HTA and reimbursement decision-making.
Methods: A systematic review of peer-reviewed and grey literature published between January 2011 and March
2018 was performed. Consulted databases were EconLit, Embase, Guidelines International Network, PsycINFO and
PubMed. A two-step strategy was used to select literature. Literature was analyzed using NVivo (QSR international).
Results: From 1015 initially identified documents, 72 were included. Most were written from an academic
perspective (61%) and focused on PP in BRA/MA and/or HTA/reimbursement (73%). Using PP to improve
understanding of patients’ valuations of treatment outcomes, patients’ benefit-risk trade-offs and preference
heterogeneity were roles identified in all three decision-making contexts. Reasons for using PP relate to the unique
insights and position of patients and the positive effect of including PP on the quality of the decision-making
process. Concerns shared across decision-making contexts included methodological questions concerning the
validity, reliability and cognitive burden of preference methods. In order to use PP, general, operational and quality
requirements were identified, including recognition of the importance of PP and ensuring patient understanding in
PP studies.
Conclusions: Despite the array of opportunities and added value of using PP throughout the different steps of the
MPLC identified in this review, their inclusion in decision-making is hampered by methodological challenges and
lack of specific guidance on how to tackle these challenges when undertaking PP studies. To support the
development of such guidance, more best practice PP studies and PP studies investigating the methodological
issues identified in this review are critically needed.
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Increasingly, the patient's perspective is considered es-
sential on all levels of decision-making throughout
the lifecycle of drugs and medical devices (i.e. the
medical product life cycle (MPLC)) [1, 2]. This is
demonstrated by a growth of literature on the roles
of patients’ perspectives in drug and medical device
development [3–5], regulatory benefit-risk assessment
(BRA), Health Technology Assessment (HTA) [6–9]
and clinical practice guideline development [10, 11].
The term ‘medical product’ will be used hereafter as
an umbrella term for drugs (or human medicinal
products) and medical devices as defined by the Euro-
pean Commission [12, 13] and the US Food and Drug
Administration (FDA) [14].
A particular area of interest is the measurement and
use of patient preferences (PP) [15, 16]. Although no
unique definition exists for PP across research fields and
disciplines [17–20], the FDA refers to PP by defining
patient preference information as “qualitative or quanti-
tative assessments of the relative desirability or accept-
ability to patients of specified alternatives or choices
among outcomes or other attributes1 that differ among
alternative health interventions” [14]. PP can be investi-
gated through qualitative and/or quantitative methods
[19]. While qualitative methods (e.g. interviews) generate
information about patient experiences and perspectives,
quantitative methods (e.g. discrete choice experiments)
collect numerical data [21].
Despite broad interest in the measurement and ap-
plication of PP, a comprehensive overview of their
specific roles and reasons to use them and the expec-
tations, concerns and requirements regarding their
use in the different decision-making contexts of the
MPLC is lacking. This literature review attempts to
address this gap by providing an overview of their po-
tential roles, and reasons for using PP, as well as the
expectations, requirements and concerns related to
their use in the following decision-making contexts of
the MPLC: i) industry processes, ii) regulatory BRA
and marketing authorization (MA), and iii) HTA and
reimbursement. Insights of this review show oppor-
tunities and challenges for the use of PP in decision-
making by all stakeholders involved in these decision-
making contexts, thereby paving the way for patient-
centric decision-making throughout the MPLC.Methods
Review context
This study was conducted as part of the Patient Pref-
erences in Benefit-Risk Assessments during the Drug1Synonyms for attributes in literature are “characteristics”, “features”,
“objects” or “criteria”.Life Cycle (PREFER) project, a five-year project that
received funding from the Innovative Medicines Ini-
tiative (IMI) 2 Joint Undertaking. PREFER aims to es-
tablish recommendations to guide industry, regulatory
authorities and HTA/reimbursement bodies on how
and when to include PP [22, 23]. While PP are gain-
ing attention, their use in decision-making remains
limited [2]. One of the first steps towards recommen-
dations about PP was therefore to understand what
hampers their current use (i.e. the challenges for their
use) and what potential decisions and steps of the
MPLC PP may inform (i.e. the opportunities). These
questions formed the basis of the review questions.Review questions and search strategy
The review was guided by the following review ques-
tions, pertaining both to the preference method itself
and the application of PP to decision-making: i) what
roles do PP have to play in the MPLC and what are
reasons to use them? (desires), ii) what is expected to
happen when PP are used in the MPLC? (expecta-
tions), iii) what concerns arise for the use of PP in
the MPLC? (concerns) and iv) what is needed in
order to use PP in the MPLC? (requirements). Search
queries were developed based upon the review ques-
tions and consisted of Medical Subject Headings
terms and free text words (Additional file 1). A pre-
liminary scoping exercise with the initially developed
search queries revealed that a large part of the litera-
ture retrieved focused on the use of PP in individual
treatment decision-making and/or on the use of PP in
the context of monitoring and biomarkers, both of
which do not form the focus of this review. There-
fore, a concept related to shared decision-making,
monitoring and biomarkers was combined to the
search query via ‘NOT’. A research librarian from
Erasmus Rotterdam University conducted the search
between January 2011 and March 2018 (so that in-
cluded documents reflect contemporary issues related
to PP) and in the following databases: EconLit,
Embase, Guidelines International Network, PsycINFO
and PubMed. Peer-reviewed publications were also
identified through hand searching and snowballing.
All PREFER collaborators were asked to share other
relevant publicly available literature (grey literature,
e.g. regulatory documents or HTA reports).
A two-step screening strategy was used (Fig. 1). First,
title and abstract of peer-reviewed publications and the
table of contents or headings of grey literature were
screened for relevance to the review questions and ex-
clusion criteria by three researchers (RJ, EvO, CW). Each
document was independently screened by two researchers
and disagreements were resolved by discussion. Second,
Fig. 1 Flowchart showing the process of identifying and selecting documents for this review. Initially, 1015 documents were retrieved. From 858
non-duplicate documents, 702 were excluded, based on a screening of their title and abstract, table of contents or headings against their
relevance to the review questions and exclusion criteria. An additional 84 documents were excluded after full text review against the in- and
exclusion criteria, resulting in a total of 72 documents included for analysis
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by one researcher (RJ).
Selection criteria
The following inclusion criteria were applied: i) litera-
ture types regulatory documents, HTA reports, pro-
ject reports and workshop reports (grey literature),
(systematic) reviews, original research articles (e.g.
published PP studies) and perspective articles (white
literature), ii) perspective: literature describing the
view of at least one of the following stakeholders was
included: academics, HTA/reimbursement bodies,
pharmaceutical or medical device industry, patients,
caregivers and patient organizations, physicians and
regulatory authorities, iii) interest: included literature
had to describe the use of a preference method in the
MPLC. Literature describing only the use of prefer-
ence methods in the context of individual treatment
decision-making or clinical practice guideline develop-
ment were excluded, iv) evaluation: only literature de-
scribing at least one of the proposed review questions
was found eligible. The following exclusion criteria
were applied: i) non-English, ii) no full text available,
iii) published before 2011 (so that included docu-
ments reflect contemporary issues related to PP), iv)non-EU or non-US (in view of the scope of this
study) and v) conference abstracts, conference notes,
book reviews and presentations.Data analysis
The following steps were undertaken by one researcher
(RJ) to analyze included literature: i) information on the lit-
erature type, stakeholder perspective and decision-making
context was extracted (Table 1, Additional file 2), ii) a cod-
ing tree was developed to code the text (Additional file 3),
iii) text was coded using the NVivo PRO 11 software (QSR
international), iv) tables were developed based upon the
structure of the coding tree using Microsoft Excel and these
tables were subsequently used to describe literature per
review question. Examples of PP studies included in the
review were added to illustrate the findings.Results
The initial search identified 1015 documents. Seventy-
two documents were included (Fig. 1, Additional file 2).
Most were: i) original research (32%) or reviews (24%),
ii) focused on PP in BRA/MA decision-making (35%),
HTA/reimbursement (21%) or both (17%) and iii)
written from an academic perspective (61%) (Table 1).
Table 1 Characteristics of included literature
Characteristics of included documents (n = 72) n %
1. Literature type
Original research 23 32
Review 17 24
Perspective article 11 15
Project report 7 10
Systematic review 4 6
Workshop report 3 4
Regulatory document 2 3
HTA report 2 3
Other 3 4
2. Main decision-making context described
BRA/MA 25 35
HTA/reimbursement 15 21
BRA/MA + HTA/reimbursement 12 17
IPDM 5 7
ITD + BRA/MA 3 4
IPDM + HTA/reimbursement + BRA/MA 3 4
IPDM + BRA/MA 4 6
ITD + BRA/MA + HTA/reimbursement 2 3
BRA/MA + HTA/reimbursement + ITD + CPG 1 1
HTA/reimbursement + IPDM 1 1
HTA/reimbursement + CPG 1 1
3. Stakeholder perspective
Academic 44 61
Regulatory authority 8 11
Industry/CRO 7 10
HTA body 3 4
Patient organization 3 4
Other 7 10
Number and percentage of included documents per literature type, main
decision-making context described and stakeholder perspective (bold font).
Each document was assigned to a stakeholder perspective: for primary
research articles, (systematic) reviews and perspective articles, the affiliation
cited of the first author was used to assign a stakeholder perspective. For
regulatory documents, the regulatory authority perspective was assigned. HTA
reports were assigned to the HTA body perspective. For project reports, since
those are written from multiple stakeholder perspectives, they could not be
assigned to a specific stakeholder perspective. HTA Health Technology
Assessment, BRA benefit-risk assessment, MA marketing authorization, IPDM
industry processes and decision-making, CPG clinical practice guideline
development, ITD individual treatment decision-making, CRO contract
research organization
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are reasons to use them? (desires)
The potential roles of PP in the MPLC can be cate-
gorized into industry processes, regulatory BRA/MA
and HTA and reimbursement (Table 2). Reasons for
using PP include reasons related to the unique in-
sights and position of patients and reasons related to
the positive effect of including PP on the quality ofthe decision-making process (Table 3). Following the
rationale that knowing how patients value treatment
benefits and risks is essential because only patients
know what it is like to live with their disease, and
the idea that patients and regulators may value bene-
fits and risks differently (Table 3), Ho et al.
conducted a first PP study to inform regulatory BRA
of medical devices for obese patients [45]. The au-
thors incorporated the attribute weights resulting
from the study in a tool that informs BRA for the
approval of new medical devices; FDA reviewers
could then compare efficacy results from clinical
trials with the minimum benefit (i.e. weight loss) re-
quired as indicated by the tool [45]. Although the
study was specifically designed to inform regulatory
MA of new devices, they state that their results
could also guide clinical trial design and post-
approval decisions (Table 2).2. What is expected to happen when PP are used in the
MPLC? (expectations)
A range of expectations were identified in the litera-
ture review. Using PP for defining treatment attri-
butes is expected to deliver improved health
outcomes for patients [14]. PP for the selection of
clinical endpoint selection is expected to: i) increase the
willingness of participants to enroll in and complete a
clinical trial, thereby accelerating clinical development [14,
32], ii) provide more meaningful results to future patients
and iii) improve the adherence of this population with the
medical product once being marketed [33, 69]. Chow
et al. [33] quantified the importance of clinical trial end-
points used in cardiovascular clinical trials according to
patients. They expect that, should these endpoints be se-
lected in cardiovascular clinical trials, results from such
trials would be perceived with greater validity by those
reviewing the trial data [33].
Use of PP in BRA/MA and HTA/reimbursement is ex-
pected to result in: i) a higher quality decision by better
alignment between the decision and patients’ values and
unmet needs [25, 38, 45, 64], ii) greater legitimacy or ac-
countability of the decision as result of taking into ac-
count clinical, social and ethical aspects of medical
products that may not be considered by a professional
panel of decision-makers [25], iii) an increased under-
standing and acceptance of the decision by the public
and stakeholders because preferences of those affected
by the decision were considered [25, 38, 63, 70], iv) more
public trust in the decision-making process [71], and v)
an increased collection of PP [64]. Finally, incorporating
PP information on subgroups for whom a specific treat-
ment will produce more benefit could increase the
effectiveness and efficiency of medical products [65].
Table 2 Potential roles of PP in the MPLC
1. Potential roles of PP in industry processes
1.1 Early development
• Informing ‘go/no-go’ decisions (e.g. internal prioritization portfolio decisions) [24]
• Informing resource allocation decisions among multiple diseases [24]
• Defining areas of unmet medical need [14, 16, 24]
• Influencing which medical product will be developed [24]
• Informing the design of a target product profile [14, 19, 27–29]
1.2 Clinical trial design
• Quantifying how clinical outcomes, benefits and risks are perceived [14, 19, 30–34]
• Indicating which clinical endpoints are of highest importance to patients [14, 31–33, 35]
• Indicating which endpoints should (not) be considered [31]
• Informing enrollment criteria and sample populations [19, 31, 33]
• Informing clinical trial sample size [27]
• Calculating acceptable levels of uncertainty (significance level and power) [36]
• Analyzing clinical trials [14, 19]
• Defining subgroups with different benefit-risk trade-offs [19, 24, 37]
1.3 Product labelling [14, 19, 37]
1.4 Post-marketing
• Subgroup PP information for suggesting new markets for present indications [37]
• Subgroup PP information for pointing to specific treatment opportunities [37]
• Informing new innovations [14]
• Redesigning and improving existing products [14, 19]
• Informing expanded indications or populations [14]
• Informing risk assessments underlying product recalls [19]
• Optimizing promotional materials [19]
1.5 Pharmacovigilance activities [19, 38, 39]
• Planning and evaluating BRAs and risk management [39]
2. Potential roles of PP in BRA/MA
• Highlighting patients’ needs for treatment [25, 26]
• Highlighting differences in views between patients and decision-makers [19, 24, 40–42]
• Highlighting situations with need for transparent communication about decision [42]
• Providing quantitative measures of how patients view their choices [24]
• Weighing (clinical) outcomes and attributes [14, 19, 25, 30, 34, 37, 38, 40, 43–48]
• Identifying most relevant outcomes to patients [14, 19, 24, 26, 37, 48, 49]
• Identifying outcomes with less perceived meaning [50]
• Providing insights into patient perspectives on other aspects of treatment (e.g. dosing) [34]
• Indicating patient benefit-risk trade-offs [18, 19, 24, 26, 34, 37, 38, 45, 47, 49, 51]
• Indicating whether patients are likely to use therapy if approved [41]
• Indicating how patients compare benefits and risks between treatment options [24]
• Indicating how patients weigh benefits and risks as the disease progresses [24]
• Enabling quantitative benefit-risk modelling in complex cases [19, 36, 37]
• Providing information on uncertainty tolerance [24, 49]
• Understanding patient heterogeneity [14, 19, 24, 37, 40, 42, 45, 52, 53]
• Tailoring MA decision based on subgroups with homogeneous preferences [14, 37, 42, 45]
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Table 2 Potential roles of PP in the MPLC (Continued)
3. Potential roles of PP in HTA/reimbursement
• Indicating patients’ preferred treatments/technologies/healthcare services [54–57]
• Indicating patients’ preferred health states (quality of life) [52]
• Indicating patients’ preferred mode of administration [52, 56]
• Indicating patients’ preferred clinical outcomes (including benefits/risks) [30, 50, 52]
• Highlighting potential differences in views between patients and decision-makers [40]
• Selecting, prioritizing or weighing endpoints and criteria [15, 18, 30, 44, 47, 50, 58]
• Highlighting the value of a treatment when the QALY is considered too narrow [59]
• Examining relative benefit-risk trade-offs [44, 54]
• Estimating willingness to pay or willingness to accept compensation [54]
• Predicting uptake rates [54]
• Indicating the general acceptability of a technology to patients [19, 56, 60]
• Providing input for economic evaluations (e.g. cost-utility analyses) [30, 47, 50, 53, 54, 61]
• Contributing to prioritization of topics for HTA [30]
• Identifying heterogeneity and segments of the patient population [52, 53]
• Tailoring reimbursement decisions based upon preference heterogeneity [52]
Potential roles of PP in the MPLC grouped per decision-making context (bold and underlined font). PP patient preferences, HTA Health Technology Assessment,
BRA benefit-risk assessment, MA marketing authorization, MPLC medical product life cycle, QALY Quality Adjusted Life Years
Table 3 Reasons for using PP in the MPLC
1. Reasons related to the unique insights of patients
• Patients have experiential knowledge of disease and treatment [16, 24, 38, 43, 54, 60, 62]
• Decision-makers and patients might have differing preferences [19, 40, 44, 58, 63]
• It challenges the opinions on the importance of endpoints [30, 52]
2. Reasons related to the unique position of patients
• Patients are the ultimate beneficiaries/end-consumers of healthcare [25, 31]
• Patients are directly affected by the decision [38, 43, 53, 54, 60, 62]
• Patients’ lives are affected by whether their concerns were considered [64]
• Patient benefit is an objective of providing healthcare services [64]
3. Reasons related to the positive effect on quality of the decision-making process
• It enables judging the consistency of decisions with patient values [64]
• It enables a more patient-centered decision-making [19, 36, 40, 52, 53, 58]
• It allows evidence-based consideration of patient perspectives [24, 36, 38, 40, 43, 45, 52, 58, 64, 65]
• It ensures patient needs are better met [25, 53, 64]
• Measurements of clinical effects usually do not sufficiently capture PP [38, 64]
• It facilitates integration of patient concerns into decision-making [66]
• It increases the effectiveness of patient involvement strategies [62]
• It solves the issue of which patients to involve directly in decision-making [38]
• It may be more representative than direct patient involvement [24, 25, 38, 40, 43, 58, 60, 62, 67, 68]
• It is required for the implementation of evidence-based medicine [64]
Reasons for using PP grouped into reasons related to the unique insights and position of patients and reasons related to the positive effect of including PP on
decision-making (bold and underlined font). PP patient preferences, MPLC medical product life cycle
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(concerns)
Concerns related to using PP in the MPLC can be catego-
rized into three types: i) general concerns (broad issues
applicable to all decision-making contexts of the MPLC,
e.g., lack of familiarity with preference methods among
stakeholders), ii) methodological concerns (those related to
measuring PP, applicable to all decision-making contexts of
the MPLC, e.g., low reliability of PP studies) and iii) con-
cerns specifically related to BRA/MA and/or HTA/reim-
bursement (issues related to PP specifically for a certain
decision-making context, e.g., lack of clarity about how to
align PP with the Quality Adjusted Life Years (QALY)
measure in HTA/reimbursement) (Table 4).The German
HTA Institute for Quality and Efficiency in Health Care
(IQWiG) piloted the preference method Analytical Hier-
archy Process (AHP) for the identification, weighting and
prioritization of outcomes for the treatment of depression
[74]. While concluding that the attribute weights resulting
from their PP study could both guide industry decisions on
clinical trial endpoint selection and HTA processes when
prioritizing outcomes, they report methodological concerns
such as correlating attributes and question the representa-
tiveness of the study population and transferability of the
results to the entire patient population [74] (Table 4).4. What is needed in order to use PP in the MPLC?
(requirements)
Requirements related to using PP across the different
decision-making contexts of the MPLC can be catego-
rized into: i) general requirements (broad aspects that
are needed to measure and use PP, e.g. guidance on
PP studies), ii) operational requirements (non-meth-
odological prerequisites related to the execution of PP
studies, e.g. regarding the timing of a PP study) and
iii) quality requirements (prerequisites that increase
the quality of the PP study, e.g. study objectivity)
(Table 5). Based on their experience from quantifying
benefit-risk preferences among rare disease patients
and caregivers, Morel et al. [51] conclude that while
researchers of novel medical products for rare diseases
should be encouraged to invest in use of preference
methods, specific regulatory guidance is needed to
acknowledge the importance of PP and to state when
in the MPLC preference methods should be used
(Table 5).Discussion
Using a systematic approach, this review identified the
potential roles and reasons to use PP (desires), as well as
the expectations, concerns and requirements regarding
their use across industry processes, BRA/MA, and HTA/
reimbursement decision-making.The three potential roles that were identified in all
three decision-making contexts involved the use of PP
to increase understanding of: i) how patients value
(clinical) outcomes of a medical product, ii) how pa-
tients make the trade-off between benefits and risks
and iii) how preferences may differ across patient
subgroups (preference heterogeneity). This finding
raises the question of whether a single PP study with
the primary objectives of investigating these three is-
sues could inform all three decision-making contexts
and address the needs respectively, of industry, HTA/
reimbursement and regulatory BRA/MA stakeholders.
One could for example imagine a PP study consisting
of: i) a qualitative phase, where patients are asked
openly about what their needs are regarding treat-
ment for their disease and what treatment attributes
they find important, and ii) a quantitative phase,
where patients are asked to choose between hypothet-
ical treatment options that differ in how they perform
on these treatment attributes. Both the results from
the qualitative phase as well as the selected attributes
and attribute weights derived from the quantitative
phase could assist industry in: i) developing a medical
product that targeted patient needs and the attributes
that patients found most important and ii) subse-
quently selecting those clinical trial endpoints based
upon the attributes patients indicated as most rele-
vant. The selected attributes and the attribute values
from the quantitative phase could also be used by
regulators and HTA/reimbursement decision-makers
to assess the clinical relevance of the outcomes of a
medical product being evaluated for MA and reim-
bursement for the disease of the included patients in
the PP study. Furthermore, the attribute values could
be used to calculate the minimum required benefit
(the minimum benefit respondents expect in order to
tolerate a specific level of risk) and the maximum ac-
ceptable risk (the maximum risk respondents are will-
ing to tolerate for a given benefit). This minimum
required benefit could be used as a reference by regu-
latory and HTA/reimbursement decision-makers, to
evaluate whether or not the clinical benefit of the
medical product, as demonstrated in clinical trials ex-
ceeds this value, i.e. whether patients would accept
the risks of the product under evaluation in return
for its benefits. If these calculations indicated that a
subgroup of patients accepted the risks in exchange
for the benefit, this could inform regulators and
HTA/reimbursement decision-makers on the market-
ing authorization or reimbursement for that subset of
patients respectively. These preferred outcomes could
also be incorporated in a novel patient relevant out-
come (PRO) instrument as, for example, explained by
Evers et al. [32], that could be used during clinical
Table 4 Concerns related to PP in MPLC
1. General concerns related to PP in industry, BRA/MA and HTA/reimbursement
• Lack of clarity and (regulatory) guidance about:
○ Definition of PP, hampering communication between stakeholders [1, 62]
○ Under what conditions to measure/use PP [1, 19]
○ For which medical product to collect PP [19, 27, 37]
○ When to conduct a PP study: before, during or after clinical development [19, 27, 37]
○ What preference method to use [19, 40, 72]
○ Which attributes to select in a PP study [19, 30, 50]
○ How to assure validity in a PP study [19, 38]
○ Whose preferences to measure (e.g. required disease experience) [19, 27, 44, 54, 73]
○ How to deal with preference heterogeneity [54]
○ Which stakeholder should collect PP [38]
○ Who is responsible for PP results and potential biases in results [38]
•Lack of familiarity among stakeholders with preference methods [16, 19, 24, 34]
•Lack of patients’ knowledge and capability of expressing preferences [62]
2. Methodological concerns related to PP in industry, BRA/MA and HTA/reimbursement
• Low validity and reliability of preference methods [19, 25, 43]
• Overlap in interpretation of attributes and interacting/overlapping attributes [30, 35, 50]
• Tension between methodologically strong methods and their cognitive burden [18, 48]
• Risk of neglecting of patient heterogeneity in PP studies [40, 52, 58]
• Elicited PP are constructed and shaped by how information is presented [62]
• Elicited PP are influenced by external factors [62]
• Heuristics, inert or flexible preferences and measurement errors [19, 24, 27, 38, 48]
• Challenge of communicating the quantitative health information to patients [14]
• Innumeracy of the participants [38, 43]
• Respondents not taking time to complete the survey of the PP study [35]
• Lack of understanding among respondents [35]
• Question framing in preference surveys [55]
• Difficulty of balancing between understandability and accuracy of questions [55]
• Ensuring representativeness of the sample [27, 50, 55]
3. Concerns specifically related to PP in BRA/MA and HTA/reimbursement
• Lack of clarity about:
○ How PP will be used and reviewed by decision-makers [19, 24, 38]
○ How to submit PP for BRA/MA and HTA/reimbursement [24, 53]
○ Standards for measuring PP for informing BRA/MA and HTA/reimbursement [24, 72]
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Table 4 Concerns related to PP in MPLC (Continued)
4. Concerns specifically related to PP in HTA/reimbursement
• Lack of clarity about:
○ Measuring patient preferences versus public preferences [54, 59, 62]
○ Measuring PP for health aspects or also for non-health aspects [1]
○ Incorporating PP in economic evaluations or not [1]
○ Using quantitative and/or qualitative PP in reimbursement decisions [1, 59]
○ Where and how to incorporate PP in current procedures [1, 18, 62]
○ How to align PP with the traditional QALY calculation [62]
○ How to conduct a systematic review on PP studies for informing HTA [60]
○ What weight PP should receive versus other decision criteria [1, 62]
• Current recommendation of HTA agencies (e.g. the UK, the Netherlands) to use generic measures, whereas PP elicited via PP studies are often
condition-specific [59]
• Current use of cost-utility analysis, which does not require quantitative PP beyond health state utilities [59]
• Low generalizability of PP study results when characteristics of healthcare system are being valued as these characteristics are often system-,
country- or culture-specific [55, 62]
• Time, funding and staff required for incorporating PP in HTA/reimbursement [1]
Concerns related to using PP in the MPLC grouped according to their nature and the decision-making context they apply to: general concerns, methodological
concerns and concerns specifically related to BRA/MA and/or HTA/reimbursement (bold and underlined font). PP patient preferences, HTA Health Technology
Assessment, BRA benefit-risk assessment, MA marketing authorization, MPLC medical product life cycle, QALY Quality Adjusted Life Years
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development performed on these PROs. Results from
such a hypothetical clinical trial could then inform: i)
regulators and HTA decision-makers regarding the
performance of that medical product in terms of
those PROs as observed during clinical development
and ii) the developer of that medical product on how
to redesign and improve the medical product in sub-
sequent development. After the MA and reimburse-
ment decision, the PRO instrument could be used to
assess how the medical product performs on these
PROs outside the clinical trial environment. This in-
formation could then inform industry on product
redesign and regulatory and HTA/reimbursement
stakeholders on continuation of MA and reimburse-
ment. Finally, if these PRO measurements indicate
that the medical product only performs well for a
subset of patients outside the clinical trial environ-
ment this could inform continuation of MA and re-
imbursement for that subset of patients only.
Despite the array of potential opportunities for the use
of PP in the MPLC listed in Table 2, there are few pub-
lished examples of the actual use of PP study results in in-
dustry, regulatory and HTA decisions [45, 82]. As
highlighted in Tables 4 and 5, a number of concerns and
gaps need to be addressed in order to advance the
measurement and use of PP in these decisions. More spe-
cifically, efforts need to focus on providing and encour-
aging: i) recognition of the importance of including PP in
industry, regulatory and HTA decisions, ii) guidance on
when and how to measure PP aiming to inform these
stakeholder decisions and iii) increased familiarity withperforming and evaluating PP studies. To promote the de-
velopment of guidance, more best practice PP studies and
more PP studies investigating the methodological con-
cerns this review identified are needed on such questions
as: i) how to select, apply and validate different preference
methods, ii) how to choose a representative sample in
order to satisfy the needs of different stakeholders and iii)
how to increase understanding of the reliability and cogni-
tive burden of different preference methods.
Although efforts to address methodological issues are
crucial, they are not sufficient alone. Efforts are also needed
to address how results from a PP study could be incorpo-
rated and aligned with current decision-making processes.
More clarity on how results from PP studies would be used
in regulatory and HTA decisions together with guidance on
how such studies should be conducted could motivate
stakeholders to conduct and submit a PP study (Table 5).
Table 5 highlights additional concerns regarding the use of
PP in HTA/reimbursement. Among the multiple ways in
which PP could inform HTA/reimbursement (Table 2), the
potential role of PP to inform QALY calculations in coun-
tries with publicly funded healthcare is under ongoing
debate. As in these countries, HTA guides the allocation of
public resources (including but not limited to patients
only), it is unclear whether public versus patient prefer-
ences should be used. Incorporation of PP in HTA/reim-
bursement bodies of such countries would therefore not
only require solving methodological questions, but also
structural and political discussions on the current HTA
process in those countries.
This review identified numerous operational and qual-
ity requirements involved in performing and evaluating
Table 5 Requirements related to PP in the MPLC
1. General requirements
• Recognition of the value of PP among stakeholders [24, 25, 39, 51, 59, 64]
• Consensus on the role of PP in decision-making [1, 62]
• More familiarity among stakeholders with PP studies [19, 34, 48, 66, 70, 72]
• More educated researchers in preference research [53]
• Resources to evaluate PP [1, 48]
• Taxonomic work for PP research [1, 60]
• Guidance on:
○ When during development to measure PP [1, 34, 51]
○ Which preference method to use in which circumstance [1, 40, 44, 56, 72]
○ Whose preferences to measure (e.g. required disease experience) [1, 19, 44]
○ Sample size [37]
○ Good research practice and quality criteria for PP studies [1, 19, 38, 43, 44, 62]
○ How to ensure validity of a PP study [75]
○ How to report about PP studies [44]
• Further research to:
○ Validate and test preference methods [37, 44, 46, 66, 76]
○ Identify methods for integrating clinical evidence in PP study analysis [50, 56]
○ Investigate methodological issues (e.g. hindsight bias) [62]
○ Compare the performance of different methods in a given situation [37]
○ Determine impact of changing list of attributes with any given method [37]
○ Explore statistical methods to detect preference heterogeneity [77]
○ Guide the development of newer methods for eliciting PP [76]
○ Assess comprehension differences by participants between methods [76]
○ Assess impact of the level of previous education on PP [33]
○ Quantify the effect of the attribute descriptions on elicited PP [78]
2. Operational requirements
• Requirements related to timing of PP study:
○ Decision depends on level of information of the treatments’ key risks [19]
○ Timing needs to be decided by sponsor [19]
○ During marketing phase to assess long-term side effects and burden [1]
• Requirements related to dealing with PP study results:
○ Stakeholders should be prepared for disappointing PP study results [24]
○ PP study results should be provided to patient community and public [24]
○ Presentation of PP study results should be tailored to the audience [79]
○ PP study results should be described transparently [56, 75]
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Table 5 Requirements related to PP in the MPLC (Continued)
3. Quality requirements
• General requirements regarding design, set-up and conduct of PP studies:
○ Selected research question should be answerable with PP study [75]
○ Study objectivity throughout PP study [24]
○ Independent design as design can influence analysis outcomes [25]
○ Extensive and forward planning [19, 27, 48]
○ Determination of objectives and attributes before design [24]
○ Design based on prior literature and preference information [19]
○ Clear definition of the patient sample and characteristics [19, 24, 49]
○ Training partners on methodology, objectives and expectations of study [79]
○ Good communication and documentation of changes to study plans [79]
○ Methodological expertise when designing and executing a PP study [24, 70]
○ Multi-stakeholder partnerships (patients, academics, industry) [24, 37, 79]
○ Interaction between decision-makers and industry in design [14, 19, 24]
○ Involvement of patients, caregivers and patient organizations [24, 42, 49, 51]
○ Application of ‘good science’ principles [1, 19, 24, 51]
○ Consideration of patient heterogeneity and cognitive burden [14, 40, 58, 75]
○ Consideration of internal and external validity [75]
○ Administration of survey by trained researchers [14]
○ Provision of tutorial for participants if self-administered survey is used [14]
○ Training of participants in elicitation tasks [40]
○ Ensuring participants’ understanding of aim and how results will be used [40]
○ Consideration of low level of health numeracy in general population [43]
• Sample requirements:
○ Sample should be heterogeneous (large samples, setting quotas) [19, 49, 75]
○ Sample should be representative of population of interest [14, 19]
○ If not possible to elicit from patients, include proxies [19, 34]
○ Sample ideally is clinical trial population [71]
○ Sample ideally is broader population than clinical trial population [41]
○ Patient should be the focus, not health care professional [14]
○ Sample should be representative of affected patients [56]
○ Sample should be representative of target population [75]
○ Sample that can yield reliable results should be drawn [24]
○ PP should come from the same population as data of effectiveness [1]
○ Both patients in remission as well as patients in recovery should be included [50]
○ Sampling should consider sociodemographic and disease characteristics [50, 61]
• Sample size requirements:
○ Adequate size so that results are generalizable to population of interest [14]
○ Sufficient size to generate acceptably robust results [24]
○ If subgroups: sufficient number in each subgroup [14]
• PP results requirements:
○ Type of PP (qualitative vs quantitative) depends on stage and decision-making context of MPLC [1, 14, 16, 19, 60]
○ Type of PP should be determined by research question [19]
○ Clinical data should be collected and used to augment PP data [42, 43]
○ Patient’s willingness and unwillingness to accept risks should be measured [14]
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Table 5 Requirements related to PP in the MPLC (Continued)
• Preference method requirements:
○ Method should be selected based on factors [1, 19, 40, 44, 76, 80]
○ Method should adhere to utility theory [18, 76]
○ Method should account for patient-relevant attributes/outcome measures [18]
○ Methods should be easy and simple for patients to understand [18]
• Requirements regarding attribute selection:
○ Research question should guide attribute and level selection [75]
○ Attributes should be broader than clinical attributes to elicit meaningful trade-offs [41]
○ Attributes should be patient-centered to investigate meaningful attributes [49]
○ Attributes should come from existing clinical trials [50, 81]
○ Selection by literature, qualitative study, asking group of medical experts or decision-makers [19]
○ Patient representatives, patients and experts should inform selection [50, 62]
○ Attributes should not overlap [30, 35, 50]
• Requirements regarding survey instrument:
○ Survey should be developed with input from multiple stakeholders [24]
○ Survey should be piloted [24, 40]
○ Survey should include screening questions, informed consent provisions, background information, training and definitions, testing, survey
questions, follow-up survey questions [24]
○ Benefit descriptions and effectiveness measures should be carefully defined [78]
○ Patients should understand objective of the elicitation tasks and how data will be used [40]
○ Questions have to be asked in an open and understandable way [18, 56, 75]
○ For choice-based preference measures, options should:
■ Be clearly described [56]
■ Have realistic advantages and disadvantages [56]
■ Be communicated to patients together with their characteristics [80]
• Requirements regarding the analysis:
○ Interpretation of results should consider the mode of sampling [68]
○ Interpretation of study results should be validated with patients [40]
○ Results should be considered with preferences from other stakeholders (clinicians, decision-makers) [68]
○ Appropriate stakeholders should interpret analysis [79]
○ Sources of uncertainty should be reported through confidence interval and/or standard error [14]
○ Written agreements about intellectual property and data use are needed [24]
Requirements related to using PP in the MPLC grouped according to their type and nature: general requirements, operational requirements and quality
requirements (bold and underlined font). PP patient preferences, MPLC medical product life cycle
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description of PP study and results when communicating
about the study, ii) applying the principles of ‘good sci-
ence’ when conducting a PP study, iii) paying attention
to the heterogeneity of PP and cognitive challenges of
preference methods, iv) ensuring patient understanding
of the questions asked in the PP study and v) ensuring a
representative and diverse sample.
Remarkably, only 18% of the included documents focused
on the use of PP in industry processes, leading to sparse re-
sults on the use PP in industry processes. As a result, fur-
ther research is warranted regarding the use of PP for
industry purposes, e.g. by consulting sources other than thepeer-reviewed literature, including those sources that use
qualitative methods such as interviews or focus groups. It
was beyond the scope and aim of this review to: i) explain
reasons why certain concerns or requirements exist and ii)
grade the results (e.g. the identified concerns and require-
ments) into a hierarchy indicating their importance.
Therefore, research aiming to address these issues could
complement the current review, e.g. by using qualitative
methods to explain the reasoning behind certain issues or
differences or by using quantitative methods aimed at
ranking and prioritizing the identified requirements and
concerns. No literature was found that described the pa-
tient’s, caregiver’s, reimbursement agency’s or (practicing)
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methodological and scientific result. Therefore, research
aiming to assess the perspectives of these different
stakeholder groups on the measurement and the use
of PP in the MPLC would complement the current
review.
The main strengths of this review are its comprehen-
siveness and novelty in using a systematic approach to
search and identify literature relevant to this topic; to
the best of the authors’ knowledge, this is the first sys-
tematic review that provides an overview of the specific
roles and the expectations, concerns and requirements
associated with using PP in different decision-making
contexts across the MPLC and for different stakeholders,
including industry, BRA/MA, and HTA/reimbursement.
This review also has limitations. The selection criteria
led to the exclusion of: i) literature focused only on PP
within individual treatment decision-making, ii) non-
English literature, iii) literature from outside the US/EU
and iv) literature that did not explicitly mention the use
of preference methods. These criteria might have re-
sulted in the exclusion of literature dealing with issues
relevant to this review. Further, the broad time span of
included literature may be viewed as a limitation since
the described concerns and requirements mentioned in
earlier published work might at this time already be
(partially) resolved and therefore this information might
not be as accurate as more recently published studies.
During coding, it was sometimes unclear to what specific
decision-making context a particular piece of text per-
tained or whether a particular piece of text needed to be
coded as a: i) desire or expectation or ii) concern or a
need. This difficulty resulted in this text being coded
into multiple domains, which in turn led to some of the
results being repeated.
Conclusions
This review highlights the numerous opportunities for using
PP in industry, BRA/MA and HTA/reimbursement deci-
sions, from early development decisions through pharma-
covigilance activities and post-marketing decisions.
However, exploiting the full potential of PP in these
decision-making contexts is currently hampered by
remaining methodological challenges and lack of specific
(regulatory) guidance on how to address these challenges
when designing and performing PP studies aiming to inform
decisions. To support the development of such guidance,
more best practice PP studies and PP studies investigating
these methodological issues are critically needed.Additional files
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